Mikhail Blagosklonny and His Bets on Rapamycin as an Anti-aging Drug

Mikhail Blagosklonny, a leading researcher in anti-aging and oncology, has bigger bets on Rapamycin as an anti-aging drug. He says that no death is without reason and most people die due to age-related diseases. Blagosklonny addresses age-related diseases, such as hypertension, atherosclerosis, Alzheimer, Parkinson disease, diabetes, and more, as bio-makers of aging. He points out that many of those are not considered as diseases as it is generally observed in people in the later ages. Blagosklonny further says that organismal aging is linked to cellular aging, a mechanistic or mammalian target of rapamycin or mTOR-dependent process. It is identified that the mTOR pathway is promoted by some growth factors such as nutrients, hormones, oxygen, and more information click here.

Blagosklonny states that mTOR activates various functions of cells that result in cellular mass growth. He identifies that mTOR causes cellular hyperfunctions and hypertrophy. Apart from the final stages of age-related diseases, the process of aging is often connected with systemic hyperfunctions such as increased platelet aggregation, increased blood pressure, hyper coagulation, hyperlipidemia, hyperinsulinemia, hyperglycemia, increased resistance to hormones, and more. It is confirmed that these hyperfunctions are making the organs damaged. Blagosklonny says that aging is a normal working process of cells and organs that are observed during the young ages.

Through his research, Blagosklonny has identified that Rapamycin can significantly reduce these hyperfunctions that cause aging at a later point in their life. He says that the drug has the ability to suppress geroconversion – the cellular basis of aging. It also goes for calorie restrictions that restrict mTOR and improve lifespan. Rapamycin is also considered as an excellent choice of drug for many age-related diseases as well. Finally, Blagosklonny also confirmed that Rapamycin could extend lifespan in all the species it was tested. Blagosklonny also identified that the drug delay cancer by slowing the aging process, and this factor makes Rapamycin as an excellent choice for cancer treatments and learn more about Mikhail.

Mikhail Blagosklonny is also a philanthropist and professor, and he is on a mission to ensure best treatment options available to every patient irrespective of their financial standing. Apart from being a researcher, he is also a mentor to aspiring researchers and his colleagues. Researchers across the world consult with him to get inputs and feedbacks on their research. By researching in oncology, Blagosklonny dreams to develop treatment procedures that are more effective and less expensive than current times. He is working on ways to remove cancerous cells from the human body without causing any damage to the healthy cells. It is identified that not harming healthy cells is important in the recovery of both body and mind after the treatment and resume him.

Blagosklonny has worked with a number of research institutes such as Roswell Park Cancer Institute, Ordway Research Institute, and more. He started his career with New York Medical College as an associate professor, immediately after completing his education. Blagosklonny has written at least 300 research papers, articles, medical reviews, and more. He also collaborated with a number of medical journals. Blagosklonny completed his M.D. and Ph.D. from the First Pavlov State Medical University and Mikhail’s lacrosse camp.